Table 2 Intraoperative characteristics
Characteristic | Sugammadex (n = 59) | Neostigmine (n = 61) |
|---|---|---|
Surgical urgency | ||
 Elective | 58 (98.3) | 60 (98.4) |
 Expedited | 1 (1.7) | 1 (1.6) |
Surgical incision | ||
 Thoracic | 13 (22.0) | 10 (16.4) |
 Upper abdominal | 19 (32.2) | 22 (36.1) |
 Lower abdominal | 27 (45.8) | 29 (47.5) |
Surgical approach | ||
 Laparoscopic/thoracoscopic | 32 (54.2) | 31 (50.8) |
 Laparoscopic/thoracoscopic assisted | 7 (11.9) | 8 (13.1) |
 Open | 20 (33.9) | 22 (36.1) |
Anaesthetic maintenance | ||
 Propofol | 7 (11.9) | 10 (16.4) |
 Volatile | 46 (78.0) | 47 (77.0) |
 Propofol + volatile | 6 (10.2) | 4 (6.6) |
Antiemetic prophylaxis | 51 (86.4) | 53 (86.9) |
Regional analgesia | 17 (28.8%) | 18 (29.5%) |
Neuromuscular blocking drug | ||
 Rocuronium | 49 (83.1) | 49 (80.3) |
 Vecuronium | 10 (16.9) | 13 (21.3) |
Neuromuscular monitoring | ||
 Quantitative ± qualitative | 28 (47.5) | 26 (42.6) |
 Qualitative alone | 27 (45.8) | 28 (45.9) |
 No monitoring | 4 (6.8) | 7 (11.5) |
Extubated in operating room | 57 (96.6) | 61 (100.0) |
TOF count at reversal | 2.0 (2.0–4.0) | 4.0 (2.0–4.0) |
Sugammadex | 56 (94.9) | 2 (3.3) |
 Dose (mg) | 200 (200–200) | 200 (0.0–200.0) |
Neostigmine | - | 59 (96.7) |
 Dose (mg) | - | 2.5 (2.5–2.5) |
TOF ratio at extubation | 1.04 (0.94–1.10) | 0.93 (0.88–1.00) |
Time from reversal to extubation (min) | 9.0 (5.5–14.0) | 10.0 (7.0–17.0) |
Further reversal | - | 9 (15.0) |
Sugammadex | - | 5 (55.6) |
Neostigmine | - | 4 (44.4) |
Duration of anaesthesia (h) | 3.8 (2.8–5.4) | 4.0 (2.7–5.0) |